Title: Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice.
Journal: Journal of biochemical and molecular toxicology20170401
Title: Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Journal: Chemico-biological interactions20161025
Title: Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes.
Journal: Toxicology20160415
Title: Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Journal: Chemistry & biology20150618
Title: Suppression of BRCA1 sensitizes cells to proteasome inhibitors.
Journal: Cell death & disease20141201
Title: Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
Journal: Chemico-biological interactions20140525
Title: Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Journal: Bone20140401
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters20130801
Title: Carfilzomib.
Journal: Blood20130207
Title: Molecular mechanisms of acquired proteasome inhibitor resistance.
Journal: Journal of medicinal chemistry20121213
Title: Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.
Journal: Drugs20121022
Title: Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20121015
Title: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Journal: Blood20121004
Title: Carfilzomib in multiple myeloma: gold, silver, or bronze?
Journal: Blood20121004
Title: An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Journal: Clinical lymphoma, myeloma & leukemia20121001
Title: A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20120901
Title: An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Journal: British journal of haematology20120901
Title: Emerging biological insights and novel treatment strategies in multiple myeloma.
Journal: Expert opinion on emerging drugs20120901
Title: Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Journal: Advances in chronic kidney disease20120901
Title: Carfilzomib in multiple myeloma.
Journal: Clinical advances in hematology & oncology : H&O20120901
Title: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Journal: Blood20120830
Title: Proteasome inhibitors in multiple myeloma: 10 years later.
Journal: Blood20120802
Title: Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.
Journal: Expert opinion on investigational drugs20120801
Title: Role of carfilzomib in the treatment of multiple myeloma.
Journal: Expert review of hematology20120801
Title: The immunoproteasome as a target in hematologic malignancies.
Journal: Seminars in hematology20120701
Title: The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Journal: Seminars in hematology20120701
Title: An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Journal: Blood20120614
Title: Proteasome inhibitors in mantle cell lymphoma.
Journal: Best practice & research. Clinical haematology20120601
Title: Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Journal: Molecular cancer therapeutics20120501
Title: Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside.
Journal: The oncologist20120501
Title: Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Journal: The Journal of pharmacology and experimental therapeutics20120401
Title: Novel therapeutics in multiple myeloma.
Journal: Hematology (Amsterdam, Netherlands)20120401
Title: Novel therapies in monoclonal gammopathies.
Journal: Hematology (Amsterdam, Netherlands)20120401
Title: Targeted therapy of multiple myeloma.
Journal: Hematology (Amsterdam, Netherlands)20120401
Title: Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Journal: Arthritis and rheumatism20120201
Title: The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20120201
Title: Next-generation proteasome blockers promise safer cancer therapy.
Journal: Nature medicine20120106
Title: Ovarian cancer: opportunity for targeted therapy.
Journal: Journal of oncology20120101
Title: Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Journal: Methods in molecular biology (Clifton, N.J.)20120101
Title: Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
Journal: PloS one20120101
Title: Novel therapies for aggressive B-cell lymphoma.
Journal: Advances in hematology20120101
Title: On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53.
Journal: PloS one20120101
Title: Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Journal: Advances in hematology20120101
Title: Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.
Journal: OncoTargets and therapy20120101
Title: Drugs: More shots on target.
Journal: Nature20111214
Title: Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Journal: Discovery medicine20111201
Title: Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.
Journal: Drug metabolism and disposition: the biological fate of chemicals20111001
Title: Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Journal: Blood20110929
Title: Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Journal: Molecular cancer therapeutics20110901
Title: [Development of novel agents for multiple myeloma; now and the future].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology20110801
Title: Novel proteasome inhibitors to overcome bortezomib resistance.
Journal: Journal of the National Cancer Institute20110706
Title: A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.
Journal: Nature genetics20110619
Title: How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.
Journal: Expert opinion on investigational drugs20110601
Title: Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Journal: European journal of haematology20110601
Title: Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
Journal: Chemistry & biology20110527
Title: Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110501
Title: Carfilzomib: a novel second-generation proteasome inhibitor.
Journal: Future oncology (London, England)20110501
Title: RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Journal: Blood20110407
Title: Recent advances in myeloma treatment.
Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis20110401
Title: Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110401
Title: Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Journal: Current cancer drug targets20110301
Title: Unfolded protein response in cancer: the physician's perspective.
Journal: Journal of hematology & oncology20110101
Title: Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.
Journal: Molecular cancer20110101
Title: Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.
Journal: Core evidence20110101
Title: Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Journal: Journal of biomedicine & biotechnology20110101
Title: Light chain (AL) amyloidosis: update on diagnosis and management.
Journal: Journal of hematology & oncology20110101
Title: Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Journal: PloS one20110101
Title: Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Journal: Investigational new drugs20101201
Title: New twists on proteasome inhibitors.
Journal: Nature biotechnology20101201
Title: Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Journal: The Biochemical journal20100915
Title: Novel disease targets and management approaches for diffuse large B-cell lymphoma.
Journal: Leukemia & lymphoma20100801
Title: Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Journal: Leukemia & lymphoma20100701
Title: The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Journal: Blood20100603
Title: Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70.
Journal: PLoS genetics20100101
Title: Bortezomib.
Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer20100101
Title: Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
Journal: Current topics in medicinal chemistry20100101
Title: State-of-the-Art Management of Complications of Myeloma and Its Treatment.
Journal: Advances in hematology20100101
Title: Proteasome inhibition and its therapeutic potential in multiple myeloma.
Journal: Biologics : targets & therapy20100101
Title: Relapsed multiple myeloma.
Journal: Hematology. American Society of Hematology. Education Program20100101
Title: Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
Journal: IDrugs : the investigational drugs journal20091201
Title: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20091115
Title: Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Journal: Leukemia20091101
Title: Proteasome inhibitors in the treatment of multiple myeloma.
Journal: Leukemia20091101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20091101
Title: Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Journal: Blood20091015
Title: Clinical development of novel proteasome inhibitors for cancer treatment.
Journal: Expert opinion on investigational drugs20090701
Title: Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Journal: Journal of medicinal chemistry20090514
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20090401
Title: Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Journal: Cardiovascular & hematological disorders drug targets20090301
Title: New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Journal: Clinical advances in hematology & oncology : H&O20090301
Title: Novel therapies for relapsed myeloma.
Journal: Hematology. American Society of Hematology. Education Program20090101
Title: Future novel single agent and combination therapies.
Journal: Cancer journal (Sudbury, Mass.)20090101
Title: Discovery of novel proteasome inhibitors using a high-content cell-based screening system.
Journal: PloS one20090101
Title: The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Journal: Advances in pharmacology (San Diego, Calif.)20090101
Title: Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.
Journal: Core evidence20090101
Title: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Journal: Blood20081001
Title: Practical considerations for multiple myeloma: an overview of recent data and current options.
Journal: Clinical lymphoma & myeloma20080801
Title: Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Journal: Blood20080601
Title: The potential of proteasome inhibitors in cancer therapy.
Journal: Expert opinion on investigational drugs20080601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20080301
Title: Mechanisms of proteasome inhibitor action and resistance in cancer.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy20080101
Title: Targeting the UPS as therapy in multiple myeloma.
Journal: BMC biochemistry20080101
Title: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Journal: Blood20071101
Title: Epoxomicin, a new antitumor agent of microbial origin.
Journal: The Journal of antibiotics19921101
Title: Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90.
Title: Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10(9):1686-97.
